Purpose:
To evaluate the outcome of AF ablation in patients with paroxysmal atrial fibrillation (AF) related tachycardia-bradycardia syndrome and to compare the efficacy of catheter ablation with a strategy of permanent pacing plus antiarrhythmic drugs (AAD). Methods: Forty-three consecutive patients with paroxysmal AF and prolonged symptomatic sinus pauses on termination of AF referred to our hospital for ablation were evaluated. According to current Guideline, each patient of this group (ABL group) was assigned with a "pacemaker recommendation level" before ablation and at the end of follow-up. In another 57 patients, paroxysmal AF was treated with anti-arrhythmic drug and a pacemaker was implanted due to AF related tachycardia-bradycardia syndrome. These patients were used as control (PM group) in the present study. Results: All the 43 patients in the ABL group fulfilled Class I indication for pacemaker implantation at baseline but they actually underwent AF ablation. Reevaluation after 20.1±9.6 months of follow-up showed that 36/43 (83.7%) patients were free from AF and no longer need a pacemaker (Class III indication) ( Figure  1a ). More patients in the PM group were on antiarrhythmic drugs (PM 40.4%, ABL 4.7%, P<0.001) while sinus rhythm maintenance at the end of follow-up was remarkably higher in the ABL group (83.7%, vs. 21.1% in PM group, P<0.001) (Figure 1b) . Conclusion: In patients with paroxysmal AF related tachycardia-bradycardia syndrome, AF ablation seems to be superior to a strategy of pacing plus AAD. Pacemaker implantation can be waived in the majority of patients after a successful ablation. Background: Radiofrequency catheter ablation (RFA) of patients with atrial fibrillation who already failed at least one antiarrhythmic drug (AAD) has previously been proven both clinical efficient and cost-effective. It has been suggested that RFA could take priority over antiarrhythmic drugs as first-line treatment, because of better efficiency treating atrial fibrillation and fewer serious side effects. The MANTRA-PAF-study (The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation) is the first published, large, randomized multicenter trial of the clinical effects of such implementation in patients with paroxysmal atrial fibrillation. Purpose: The aim of this study was to evaluate the cost-effectiveness of treating paroxysmal atrial fibrillation with radiofrequency catheter ablation as first-line treatment.
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Methods and results:
Costs and clinical effects for the first two years were calculated direct from MANTRA-PAF data. A decision analytic Markov-model was developed to study long-term (life-long) effects and costs of RFA compared to AAD as first-line treatment. Small positive clinical effects were found in the overall population, a gain of average 0.06 QALYs to an incremental cost of 3,033 resulting in an incremental cost-effectiveness ratio (ICER) of 50,570 /QALY. However, the result of the subgroup analyses indicates that a major part of the positive clinical effects for the overall population were from the quartile (26%) of the youngest patients (≤50 years). Older patients were also relatively costly to treat while younger were almost cost neutral when using a life-long perspective. The ICER of a 45 years old patient was approximately 3,434 /QALY, while corresponding ICER of a 65 years old patient was 108,937 /QALY. Conclusion: Cather ablation seems to be a cost-effective treatment option for patients below 50 years with paroxysmal atrial fibrillation. However, the effectiveness in older patients is uncertain. Background: MANTRA-PAF is a large randomized multicenter trial comparing radiofrequency catheter ablation (RFA) and antiarrhythmic drug (AAD) therapy as first line treatment of paroxysmal atrial fibrillation (PAF). Intention-to-treat analysis showed no significant difference in cumulative AF burden, but at 24 months AF burden was significantly lower in the RFA than in the AAD group. In the present on-treatment analysis we compared three groups of patients: those who received only the prescribed treatment (pure RFA and pure AAD groups) and those treated with combination of RFA and AAD (cross-over group). Methods: A total of 294 AAD naïve patients with PAF were randomly assigned to RFA (146 patients) or class IC/III AAD therapy (148 patients). Cumulative and pervisit AF burden (i.e., percentage of time in AF) was evaluated from 7-day Holter recordings at baseline and after 3, 6, 12, 18, and 24 months. The patients were considered free from AF if no AF episodes longer than 60 s were detected. In the AAD group, 54 patients (36%) underwent supplementary ablation and in the RFA group 30 patients (21%) received antiarrhythmic medication after the 3 months blanking period (at 24 months 9% were on AAD). Eight patients were excluded from the analysis because they did not receive the index treatment.
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Results: At 24 months, AF burden was significantly lower in the pure RFA group (n=110) than in the pure AAD (n=92) and the cross-over (n=84) groups (90th percentile 1% vs. 10% vs. 19%, P=0.007), and more patients in the RFA than in the other groups were free from any AF (89% vs. 73% vs. 74%, P =0.006). The cumulative AF burden was significantly lower in the pure RFA and AAD groups than in the cross-over group (90th percentile 10% vs. 6% vs. 24%, P<0.001).
During the 2 year follow-up period 63%, 59% and 21% (P<0.001) of the patients in the pure RFA, pure AAD and the cross-over group had no AF episodes in any Holter recording, respectively. There was no significant difference in the number of severe complications between the groups. Conclusions: These data indicate that RFA is superior to AAD as first line treatment in a large subset of patients with highly symptomatic PAF. The results are pertinent among relatively young and healthy subjects and should not be extrapolated to elderly patients or to those with comorbidities.
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